Oncorus Announces Workforce Reduction Plan
01 juin 2023 16h05 HE
|
Oncorus, Inc.
ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes...
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
22 mai 2023 16h05 HE
|
Oncorus, Inc.
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May ...
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
24 mars 2023 07h00 HE
|
Oncorus, Inc.
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support...
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
04 janv. 2023 07h00 HE
|
Oncorus, Inc.
Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertiseOpportunity for...
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
30 nov. 2022 07h00 HE
|
Oncorus, Inc.
Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in...
Oncorus to Participate in Upcoming Investor Conferences
23 nov. 2022 08h00 HE
|
Oncorus, Inc.
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
18 nov. 2022 08h00 HE
|
Oncorus, Inc.
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical...
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
02 nov. 2022 07h00 HE
|
Oncorus, Inc.
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022On track to submit IND for ONCR-021 in mid-2023Completed...
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
07 oct. 2022 09h00 HE
|
Oncorus, Inc.
ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients,...
Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference
26 sept. 2022 07h00 HE
|
Oncorus, Inc.
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...